Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Isolated limb perfusion a… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Isolated limb perfusion as a treatment option for rare types of tumours

Artikel i vetenskaplig tidskrift
Författare Valerio Belgrano
Ilan Ben-Shabat
Peter Bergh
Roger Olofsson Bagge
Publicerad i International Journal of Hyperthermia
Volym 32
Nummer/häfte 6
Sidor 595-599
ISSN 0265-6736
Publiceringsår 2016
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för kirurgi
Institutionen för kliniska vetenskaper, Avdelningen för ortopedi
Sidor 595-599
Språk en
Länkar dx.doi.org/10.1080/02656736.2016.11...
Ämnesord Advanced status, isolated limb perfusion, local control, rare tumours, necrosis-factor-alpha, soft-tissue sarcomas, t-cell lymphoma, malignant-melanoma, regional perfusion, complete remission, tnf-alpha, melphalan, extremities, carcinoma, Oncology, Radiology, Nuclear Medicine & Medical Imaging
Ämneskategorier Klinisk medicin

Sammanfattning

Background: Isolated limb perfusion (ILP) is an established and effective treatment for advanced melanoma and soft tissue sarcomas of the extremities with a high overall response rate. The aim of this study was to describe our experience of ILP for more rare types of tumours. Methods: Patients with Merkel cell carcinoma (MCC) (n = 4), squamous cell carcinoma (SCC) (n = 2), B-cell lymphoma (n = 1), desmoid tumours (n = 3), pigmented villonodular synovitis (PVNS) (n = 1) and giant cell tumour (n = 1) were treated with ILP and analysed retrospectively. Results: The four patients with in-transit MCC had three complete responses (CR) and one partial response (PR); the two patients with SCC had one CR and one stable disease (SD); the patients with desmoid tumours had two PR and one SD. A CR was also observed for the patient with a giant cell tumour, but the patient with PVNS had a SD. The patient with cutaneous metastases of B-cell lymphoma showed a CR, however with rapid systemic progression. Local toxicity according to Wieberdink was grade II in 10 patients (83%) and grade III in two patients (17%). Conclusions: These results show that ILP can be used as a treatment option also for more rare disease entities when other treatments have failed.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?